Quick Takeaways: Why It Matters? Dechra’s Boston HQ move and community-facing strategy signal how veterinary pharma is increasingly aligning with mainstream human health and life sciences ecosystems, not just traditional animal-health hubs, which could intensify competition for talent, par...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Quick Takeaways: Why It Matters? CompanAIn’s Veterinary Portal broadens its AI pet-wellness platform from owner-facing tools into a shared clinical workflow, which could make the product stickier for clinics and more valuable for longitudinal care. By giving vets ...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways: Why It Matters? Elanco Ventures adds a structured, early-stage venture arm to Elanco’s strategy, giving the company a dedicated channel to access and co-develop emerging animal health technologies before they become mature competitors or acquisition targets. The ...
Quick Takeaways: Why It Matters? The commercial launch creates a multi-species, video-first monitoring layer that sits between home/owner observation and veterinary care, turning smartphones and connected cameras into continuous health sensors for pets, livestock, wildlife, and c...
Quick Takeaways: Why It Matters? Comfort Zone Cat Calming Mousse expands the brand’s cat-calming portfolio into a high-utility, lickable format that addresses a key friction point: many cats resist capsules or tablets, so a flavor-driven mousse with natural salmon/chicken and L-T...
Quick Takeaways: Why It Matters? AKS-699 is being positioned as a long-interval, owner-friendly alternative to monthly IL‑31 biologics like Cytopoint in canine atopic dermatitis. The favorable efficacy and tolerability profile in preclinical work (only mild, transient injection-site r...
Quick Takeaways: Why It Matters? Elanco is tightening its premium position in canine vaccines by launching the first 0.5 mL combo shot that covers both Lyme disease and leptospirosis in a single, low-volume dose, using its PureFil technology to support fewer reactions and more co...
Quick Takeaways: Why It Matters? Gelteq’s canine palatability trials with Kemin confirm that its gel-based delivery platform can effectively mask bitter compounds and deliver strong acceptance across multiple flavor profiles, even with naturally unpalatable ingredients. This is a key enabl...
